

Cobolimab

Cat. No.:	HY-P99827
CAS No.:	2022215-65-0
Target:	Tim3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC ₅₀ value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) ^{[1][2][3]} .
In Vitro	Cobolimab (0.0001-10 nM; 3 d) promotes TIM-3 internalization in a dose dependent manner in pre-activated T cells with an IC ₅₀ value of 0.4464 nM ^[3] . Cobolimab (20 µg/mL; 24 h) significantly increases CD8 ⁺ T cell content by inhibiting TIM-3 ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022.
- [2]. Markham A. Dostarlimab: First Approval. *Drugs*. 2021 Jul;81(10):1213-1219.
- [3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. *Antib Ther*. 2020 Nov 9;3(4):227-236.
- [4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. *Ann Transl Med*. 2021 Sep;9(18):1447.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA